BioCentury
ARTICLE | Clinical News

Ibudilast: Phase II start

September 17, 2012 7:00 AM UTC

Early next year, MediciNova will begin a 12-week, placebo-controlled, U.S. Phase II trial to evaluate 100 mg daily ibudilast in 140 patients, including about 70 HIV-positive patients. The Center for B...